Current approaches and challenges in monitoring treatment responses in breast cancer

Journal of Cancer

Volumn 5, Issue 1, 2014, Pages 58-68

  Graham, Lindsey J ^a   Shupe, Matthew P ^a   Schneble, Erika J ^a   Flynt, Frederick L ^a   Clemenshaw, Michael N ^a   Kirkpatrick, Aaron D ^a   Gallagher, Chris ^b   Nissan, Aviram ^c   Henry, Leonard ^d   Stojadinovic, Alexander ^e   Peoples, George E ^a   Shumway, Nathan M ^a  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d IU Health Goshen Center for Cancer Care   (United States)

^e Bon Secours Cancer Institute   (United States)

Author keywords

Adjuvant; Breast cancer; Future directions; Metastatic; Neo adjuvant; Treatment monitoring

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 27.29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH DIFFERENTIATION FACTOR 3; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOASSAY; LONG TERM SURVIVAL; MAMMOGRAPHY; MASTECTOMY; METASTASIS; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT MONITORING; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

EID: 84893584450     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7047     Document Type: Review

References (75)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-41. doi:10.3322/caac.21149.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-92. doi:10.1056/NEJMoa050518.
3. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012. doi:10.1016/S0140-6736(12)61963-1.
4. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008; 26: 1980-6. doi:10.1200/JCO.2007.10.8399.
5. Ploos van Amstel FK, van den Berg SW, van Laarhoven HW, Gielissen MF, Prins JB, Ottevanger PB. Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer. 2013. doi:10.1007/s00520-013-1764-0.
6. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002; 184: 383-93. doi:S0002961002010127 [pii].
7. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305: 569-75. doi:10.1001/jama.2011.90.
8. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-106. doi:10.1016/S0140-6736(05)67887-7.
9. Houssami N, Ciatto S. Mammographic surveillance in women with a personal history of breast cancer: how accurate? How effective? Breast. 2010; 19: 439-45. doi:10.1016/j.breast.2010.05.010.
10. Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009; 114: 403-12. doi:10.1007/s10549-008-0023-4.
11. Orel SG, Fowble BL, Solin LJ, Schultz DJ, Conant EF, Troupin RH. Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: prognostic significance of detection method. Radiology. 1993; 188: 189-94.
12. Arasu VA, Joe BN, Lvoff NM, Leung JW, Brenner RJ, Flowers CI, et al. Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology. 2012; 264: 371-7. doi:10.1148/radiol.12111458.
13. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast Cancer. Journal of the National Comprehensive Cancer Network. 2009; 7: 122-92.
14. Khatcheressian J, Hurley P, Bentug E, Esserman LJ, Grunfeld E, Halberg F. Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2013; 31: 961-5.
15. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-312. doi:10.1200/JCO.2007.14.2364.
16. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): breast cancer-version 3.2013. 2013.
17. Gunia SR, Merrigan TL, Poulton TB, Mamounas EP. Evaluation of appropriate short-term mammographic surveillance in patients who undergo breast-conserving Surgery (BCS). Ann Surg Oncol. 2012; 19: 3139-43. doi:10.1245/s10434-012-2578-x.
18. Lin K, Eradat J, Mehta NH, Bent C, Lee SP, Apple SK, et al. Is a short-interval postradiation mammogram necessary after conservative surgery and radiation in breast cancer? Int J Radiat Oncol Biol Phys. 2008; 72: 1041-7. doi:10.1016/j.ijrobp.2008.02.017.
19. McNaul D, Darke M, Garg M, Dale P. An evaluation of post-lumpectomy recurrence rates: is follow-up every 6 months for 2 years needed? J Surg Oncol. 2013; 107: 597-601. doi:10.1002/jso.23298.
20. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer. Journal of the American College of Radiology. 2010; 7: 18-27. doi:10.1016/j.jacr.2009.09.022.
21. Dershaw DD. Mammography in patients with breast cancer treated by breast conservation (lumpectomy with or without radiation). AJR Am J Roentgenol. 1995; 164: 309-16. doi:10.2214/ajr.164.2.7839960.
22. Brennan S, Liberman L, Dershaw DD, Morris E. Breast MRI screening of women with a personal history of breast cancer. AJR Am J Roentgenol. 2010; 195: 510-6. doi:10.2214/AJR.09.3573.
23. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007; 356: 1295-303. doi:10.1056/NEJMoa065447.
24. Liberman L, Morris EA, Dershaw DD, Abramson AF, Tan LK. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol. 2003; 180: 901-10. doi:10.2214/ajr.180.4.1800901.
25. Quinn EM, Coveney AP, Redmond HP. Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. Ann Surg Oncol. 2012; 19: 3035-41. doi:10.1245/s10434-012-2341-3.
26. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012; 307: 1394-404. doi:10.1001/jama.2012.388.
27. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89. doi:57/2/75 [pii].
28. Barnsley GP, Grunfeld E, Coyle D, Paszat L. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg. 2007; 120: 1125-32. doi:10.1097/01.prs.0000279143.66781.9a.
29. Destounis S, Morgan R, Arieno A, Seifert P, Somerville P, Murphy P. A review of breast imaging following mastectomy with or without reconstruction in an outpatient community center. Breast Cancer. 2011; 18: 259-67. doi:10.1007/s12282-011-0287-0.
30. Helvie MA, Bailey JE, Roubidoux MA, Pass HA, Chang AE, Pierce LJ, et al. Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology. 2002; 224: 211-6.
31. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994; 271: 1593-7.
32. Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999; 281: 1586. doi:jlt0505 [pii].
33. Montgomery D, Krupa K, Cooke T. Follow up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. British Journal of Cancer. 2007; 97: 10.
34. Grunfeld E, Fitzpatrick R, Mant D, Yudkin P, Adewuyi-Dalton R, Stewart J, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract. 1999; 49: 705-10.
35. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology. 1998; 16: 2672-85.
36. Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin North Am. 2013; 93: 493-9. doi:10.1016/j.suc.2013.01.006.
37. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009; 250: 558-66. doi:10.1097/SLA.0b013e3181b8fd5e.
38. Argus A. Clinical Indications for breast MR. Applied Radiology. 2010; 39: 10-9.
39. Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013; 105: 321-33. doi:10.1093/jnci/djs528.
40. Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010; 254: 357-66. doi:10.1148/radiol.2542090405.
41. Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011; 18: 3160-3. doi:10.1245/s10434-011-1919-5.
42. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-16.
43. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47. doi:10.1016/j.ejca.2008.10.026.
44. Gold LS, Buist DSM, Loggers ET, Etzioni R, Kessler L, Ramsey SD, et al. Advanced Diagnostic Breast Cancer Imaging: Variation and Patterns of Care in Washington State. Journal of Oncology Practice. 2013. doi:10.1200/jop.2012.000796.
45. Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol. 2012; 53: 615-27. doi:10.1258/ar.2012.110603.
46. Precht LM, Lowe K, Atwood M, Beatty D. Neoadjuvant Chemotherapy of Breast Cancer: Tumor Markers as Predictors of Pathologic Response, Recurrence, and Survival. The Breast Journal. 2010; 16: 8.
47. Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;6:220.
48. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the Clinical Management of Breast Cancer. Radiology. 2013; 266: 388-405. doi:10.1148/radiol.12110853.
49. Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashimben O, et al. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol. 2011; 80: 828-33. doi:10.1016/j.ejrad.2010.04.029.
50. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000; 26: 91-102. doi:10.1053/ctrv.1999.0151.
51. Wu LM, Hu J, Gu HY, Hua J, Xu JR. Can diffusion-weighted magnetic resonance imaging (DW-MRI) alone be used as a reliable sequence for the preoperative detection and characterisation of hepatic metastases? A meta-analysis. Eur J Cancer. 2013; 49: 572-84. doi:10.1016/j.ejca.2012.08.021.
52. Kufe DW. Mucins in cancer: function, prognosis, and therapy. Nat Rev Cancer. 2009; 9: 874-85.
53. Taylor-Papadimitriou J. Report on the first international workshop on carcinoma-associated mucins. Int J Cancer. 1991; 49: 1-5.
54. Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 1985; 75: 1671-8. doi:10.1172/JCI111875.
55. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010; 411: 1869-74. doi:10.1016/j.cca.2010.08.039.
56. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol. 1997; 15: 2322-8.
57. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem. 1999; 45: 630-7.
58. Klee GG, Schreiber WE. MUC1 Gene-Derived Glycoprotein Assays for Monitoring Breast Cancer (CA 15-3, CA 27.29, BR). Arch Pathol Lab Med. 2004; 128: 1131-5.
59. Hayes DF, Zurawski VR, Jr., Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986; 4: 1542-50.
60. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984; 3: 223-32.
61. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 1988; 48: 4107-12.
62. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983; 249: 1881-6.
63. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001; 7: 2357-62.
64. Lokich JJ. CEA: a monitor of therapy for breast and colon cancer. Am Fam Physician. 1978; 17: 173-6.
65. Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, et al. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol. 1986; 4: 46-56.
66. Woo KB, Waalkes TP, Ahmann DL, Tormey DC, Gehrke CW, Oliverio VT. A quantitative approach to determining disease response during therapy using multiple biologic markers: application to carcinoma of the breast. Cancer. 1978; 41: 1685-703.
67. Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol. 2012; 23: 338-45. doi:10.1093/annonc/mdr154.
68. Baskic D, Ristic P, Matic S, Bankovic D, Popovic S, Arsenijevic N. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers. 2007; 12: 657-67. doi:10.1080/13547500701520563.
69. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994; 30A: 2082-4.
70. van Dalen A. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res. 1996; 16: 2345-9.
71. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer. 1999; 35: 47-53.
72. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer. 2004; 11: 389-95.
73. Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, et al. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat. 2009; 118: 89-97. doi:10.1007/s10549-009-0377-2.
74. Wu SC, Chou FF, Rau KM. Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat. 2010; 124: 879-82. doi:10.1007/s10549-010-1117-3.
75. Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat. 2006; 98: 241-8. doi:10.1007/s10549-005-9155-y.